Suppr超能文献

选择性 5-羟色胺再摄取抑制剂与畸形:尘埃落定?

Selective serotonin reuptake inhibitors and malformations: case closed?

机构信息

The Motherisk Program, Division of Clinical Pharmacology/Toxicology, Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada.

出版信息

Semin Fetal Neonatal Med. 2013 Feb;18(1):19-22. doi: 10.1016/j.siny.2012.10.004. Epub 2012 Nov 24.

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are widely used by pregnant women due to the high rates of depression among reproductive-age women. Several studies based on administrative databases reported an increased risk of cardiac malformations among infants of pregnant users. This has caused anxiety and fears among expecting women and their physicians, often leading to discontinuation of much-needed therapies. Recent decisive evidence documented a similar higher risk of cardiac malformations among depressed women not taking SSRIs during pregnancy. The most likely reason is ascertainment bias, with depressed women, treated or untreated, undergoing significantly more diagnostic tests in their children. These data strongly support the view that SSRIs do not increase the risk of cardiovascular malformations.

摘要

选择性 5-羟色胺再摄取抑制剂(SSRIs)在孕妇中广泛使用,因为生育年龄妇女的抑郁症发病率很高。一些基于行政数据库的研究报告称,孕妇使用 SSRIs 会增加婴儿心脏畸形的风险。这引起了孕妇及其医生的焦虑和担忧,通常导致许多急需的治疗被中断。最近的决定性证据表明,在怀孕期间未服用 SSRIs 的抑郁妇女,其婴儿患心脏畸形的风险也更高。最可能的原因是确定偏差,即接受治疗或未接受治疗的抑郁妇女,其子女接受的诊断性检查明显更多。这些数据有力地支持了 SSRIs 不会增加心血管畸形风险的观点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验